Figure 4From: Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modellingPredicted dihydroartemisinin-piperaquine treatment outcome per age group (in years) in an African population of 10,000 individuals dosed by (A) age or (B) weight and last dose skipped (i e, patients receive one dose daily over two days given at 0Â h and 24Â h). Black triangles indicate the cut-off points of the age-based dosing bands.Back to article page